Emerging infections: surveillance, epidemiology and pathogenesis

项目总结 在过去的25年里，由于气候变化，壁虱传播疾病的发病率显著增加， 人类和扁虱不断变化的人口结构，以及媒介控制不足。包括经济方面的 以及社会成本，据估计，扁虱传播的疾病每年造成500亿至1000亿美元的损失。 疾病控制和预防中心目前识别了18种不同的扁虱传播病原体 美国。随着每年都有新的病毒和病原体被发现，这个数字可能还会上升。 其中一个病原体是波旁病毒(BRBV)，这是一种新出现的扁虱传播的RNA病毒，可以感染和引起 人类的疾病。目前还没有可用的抗病毒疗法或疫苗，这突显了开发 针对这些危及生命的疾病的对策。此应用程序的主要目标是开发 制备BRBV基因疫苗，在BRBV小鼠模型上评价其体内免疫效果，并测定其免疫原性。 作用机制。第二个目标是测试不同的病毒抗原和mrna疫苗设计，以改进 多价基因疫苗。成功完成拟议研究将为以下工作提供初步数据 一个R01应用程序，旨在开发一种通用疫苗，提供对壁虱和壁虱传播的保护 美国的病原体。

PROJECT SUMMARY The incidence of tick-borne diseases has increased significantly over the past 25 years due to climate change, shifting population demographics of both humans and ticks, and inadequate vector control. Including economic and societal costs, it is estimated that tick-borne diseases costs between 50 and 100 billion dollars each year. The Center for Disease Control and Prevention currently recognizes 18 different tick-transmitted pathogens in the United States. This number is likely to rise as novel viruses and pathogens are being discovered each year. One of these pathogens is Bourbon virus (BRBV), an emerging tick-borne RNA virus that can infect and cause disease in humans. No antiviral therapies or vaccines are available, highlighting the need to develop countermeasures against these life-threatening diseases. The primary objective of this application is to develop an mRNA vaccine against BRBV, evaluate its efficacy in vivo in a mouse model of BRBV and determine the mechanism of action. A secondary goal is to test different viral antigens and mRNA vaccine designs to improve multivalent mRNA vaccines. Successful completion of the proposed studies will provide the preliminary data for a R01 application aimed at developing a universal vaccine that confers protection against tick and tick-borne pathogens in the United States.